PRGO — Perrigo Company plc

Is PRGO overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Neutral As of October 3, 2026

Perrigo Company plc (PRGO) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $14.26. The rating moved from Overbought to Neutral on October 1, 2026.

AI analysis

The company benefits from recurring retailer relationships and scale in contract manufacturing, but growth is constrained by pricing pressure from retailers, input-cost inflation, and limited near-term product catalysts. Key near-term drivers will be execution on cost-savings, margin stabilization, and any balance-sheet actions that improve strategic optionality; adverse developments in supply-chain costs, regulatory inspections, or weaker consumer demand would weigh on results.

Key factors

  • Stable consumer-health / OTC revenue base with defensive demand characteristics that can support steady cash flow in risk-off markets
  • Operational cost pressure from global supply-chain and raw-material inflation that can compress gross margins if not offset by pricing or efficiency gains
  • Large share of private‑label manufacturing and retailer relationships provide recurring volume but expose pricing leverage to major retailers
  • Potential for margin recovery via ongoing cost-savings, manufacturing rationalization and SKU optimization programs
  • Balance-sheet and liquidity position (debt servicing and cash flow) will drive strategic optionality for targeted M&A or shareholder returns
  • Limited visibility on near-term catalysts; sector rotation into defensive names could provide short-term support, while broader healthcare policy (drug pricing) has mixed relevance

Risks

  • Sustained input-cost inflation and freight/energy dislocations that further pressure margins and force promotional activity
  • Aggressive pricing and private‑label competition from retailers leading to margin erosion and volume mix shifts
  • Macroeconomic weakness reducing discretionary consumer spending on non-essential care items
  • Regulatory or litigation exposures (product, safety, or manufacturing inspections) that could create recalls or remediation costs
  • Currency volatility in international markets given Perrigo's global footprint
  • Limited near-term growth catalysts; failure to achieve targeted cost savings or integration benefits following any acquisitions

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for PRGO — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.